Pharmacologic adjunctive to insulin therapies in type 1 diabetes: The journey has just begun

doi:10.4239/wjd.v10.i4.234

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7747)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

302

WORD

148

HTML

4868

Tables (1-2)

198

Sum=5516

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

866

Download

1365

Sum=2231

Apr 15, 2019 (publication date) through Jul 26, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Diabetes. Apr 15, 2019; 10(4): 234-240
Published online Apr 15, 2019. doi: 10.4239/wjd.v10.i4.234

Table 2 Main limitations of available evidence on the use of various drugs as adjunctive treatments in type 1 diabetes

Limitations of clinical trials	Small number of studies and patients involved
	Heterogeneity in study designs and explored outcomes
	“Conventional” outcomes explored: changes in HbA1_C, body weight and insulin dose. Data on glycemic variability, IR and OS markers are scarce
	Not taking into account the clinical heterogeneity of patients with T1D
	Trials exploring the effects of adjunctive treatments on “hard” CVD end points in T1D patients are currently unavailable

HbA1_C: Glycated hemoglobin A1_C; T1D: Type 1 diabetes; CVD: Cardiovascular disease; IR: Insulin resistance; OS: Oxidative stress.

Citation: Karras SN, Koufakis T, Zebekakis P, Kotsa K. Pharmacologic adjunctive to insulin therapies in type 1 diabetes: The journey has just begun. World J Diabetes 2019; 10(4): 234-240
URL: https://www.wjgnet.com/1948-9358/full/v10/i4/234.htm
DOI: https://dx.doi.org/10.4239/wjd.v10.i4.234